A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(38 sites)

United States

Local Institution - 0042, Birmingham, Alabama

Local Institution - 0041, Los Angeles, California

Local Institution - 0014, Washington D.C., District of Columbia

Local Institution - 0022, Hollywood, Florida

Local Institution - 0045, Miami, Florida

Local Institution - 0049, Atlanta, Georgia

Local Institution - 0033, Chicago, Illinois

Local Institution - 0017, Baltimore, Maryland

Local Institution - 0044, Boston, Massachusetts

Local Institution - 0043, St Louis, Missouri

Local Institution - 0024, Durham, North Carolina

Local Institution - 0025, Cincinnati, Ohio

Local Institution - 0048, Cleveland, Ohio